News >

GVHD Armamentarium Expanding, But Novel Treatments Still Needed

Brittany Cote
Published: Friday, Mar 06, 2020

Madan Jagasia, MD, MBBS, chief medical officer, Translational Research and Interventional Oncology Research Program, George and Beverly Rawlings Directorship, professor of medicine, Vanderbilt-Ingram Cancer Center

Madan Jagasia, MD, MBBS

Though treatment options for patients with graft-versus-host-disease (GVHD) are available, there is a need to explore more effective therapies in clinical trials, especially for those who have steroid-refractory disease and progress on ruxolitinib (Jakafi), explained Madan Jagasia, MBBS, MS, MMHC.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication